What regulatory and scientific evidence can I use to demonstrate that grapefruit in spirits like London Dry Gin does not interact with medications like statins?

Members working in spirits face repeated questions from consumers about whether grapefruit in their products will interact with statin medications. The key scientific argument centres on the thermochemistry of the compounds responsible for the interaction.

The active compounds causing statin interactions are **furanocoumarins**, which inhibit the cytochrome P450 enzyme system that metabolises statins in the liver. Furanocoumarins have a boiling point of approximately **300°C**, well above typical spirit distillation temperatures (89–90°C). Since the vapour pressure of these compounds is negligible at distillation temperatures, furanocoumarins do not carry over into the distillate during production. This means grapefruit-infused spirits produced via distillation should contain no active furanocoumarins capable of interacting with medication.

Members recommend: - **PubChem (NCBI)** — cited as a reliable source for technical data on bergapten and other furanocoumarins: https://pubchem.ncbi.nlm.nih.gov/compound/Bergapten - **EFSA (European Food Safety Authority) allergen paper** — https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2007.482 — useful for regulatory reference, though primarily focused on nut allergens

**Caveats:** Members noted that even with printed technical evidence, some consumers remain unconvinced and may continue to raise objections at events. Having the scientific data on hand is useful for addressing concerns, though it may not satisfy all customers.